

1 Robert V. Prongay (SBN 270796)
 2 Pavithra Rajesh (SBN 323055)
3 GLANCY PRONGAY & MURRAY LLP
 4 1925 Century Park East, Suite 2100
 Los Angeles, California 90067
 Telephone:(310) 201-9150
 5 Facsimile: (310) 201-9160
 6 Email: rprongay@glancylaw.com
 prajesh@glancylaw.com

7
 8 *Attorneys for Lead Plaintiffs Ervin Derr*
and Peter Shoemaker

9 [Additional Counsel on Signature Page]

10 **UNITED STATES DISTRICT COURT**
 11 **SOUTHERN DISTRICT OF CALIFORNIA**

13 ERVIN DERR, and PETER
 14 SHOEMAKER, Individually and on
 15 Behalf of All Others Similarly Situated,

16 Plaintiff,

17 v.

18 RA MEDICAL SYSTEMS, INC.,
 DEAN IRWIN, ANDREW JACKSON,
 19 MELISSA BURSTEIN, MARTIN
 BURSTEIN, RICHARD HEYMANN,
 MAURICE BUCHBINDER, MARTIN
 20 COLOMBATTO, RICHARD MEJIA,
 JR., MARK E. SAAD, and WILLIAM
 21 ENQUIST, JR.,

22 Defendants.

Case No. 3:19-cv-01079-LAB-AHG
SECOND AMENDED COMPLAINT
 The Hon. Larry Alan Burns

23
 24
 25
 26
 27
 28

TABLE OF CONTENTS

1

2 I. INTRODUCTION..... 1

3

4 II. JURISDICTION AND VENUE..... 6

5 III. PARTIES..... 6

6 IV. PLAINTIFFS PURCHASED RA MEDICAL SHARES PURSUANT OR

7 TRACEABLE TO THE REGISTRATION STATEMENT 11

8 V. CLASS ACTION ALLEGATIONS..... 13

9 VI. BACKGROUND..... 14

10 A. Company Overview 14

11 B. Ra Medical Must Comply With Strict FDA Regulations..... 15

12 1. FDA Limits The Intended Use Of DABRA To Treat Certain

13 Forms Of PAD 16

14 2. Ra Medical Can Only Market DABRA For Its Intended Use.... 16

15 3. If Ra Medical Initiates Any Correction Or Recall Of DABRA, It

16 Must Notify The FDA 17

17 4. Ra Medical Must Notify The FDA If DABRA Malfunctions.... 17

18 C. Unbeknownst To Investors, The FDA Warned Ra Medical Prior To

19 The IPO That The Company Was Improperly Engaging In Off-Label

20 Marketing 18

21 D. Before The IPO, Ra Medical Denied Allegations Of Off-Label

22 Marketing In Connection With A Dispute With Strata Skin Sciences,

23 Inc..... 20

24 VII. SUMMARY OF DEFENDANTS’ VIOLATIONS OF THE SECURITIES

25 ACT 23

26 A. The Company Completed The IPO..... 23

27

28

1 B. The Registration Statement Contained Untrue Statements Of Material
2 Facts And/Or Omitted To State Material Facts Required To Be Stated
3 Therein Or Necessary To Make The Statements Therein Not
4 Misleading..... 23

5 C. Defendants Admit That Statements In The Registration Statement Were
6 Untrue And/Or Omitted Material Information 26

7 D. Investors Who Bought Ra Medical Stock Pursuant And/Or Traceable
8 To The IPO Suffered Substantial Losses 28

9 VIII. SUMMARY OF DEFENDANTS’ VIOLATIONS OF THE EXCHANGE
10 ACT 29

11 A. When Ra Medical Went Public, Its DABRA Catheter Presented Strong
12 Prospects For Future Sales Growth..... 29

13 B. After The IPO, Ra Medical Touts Positive Progress In Expanding Its
14 Salesforce And Denies Claims Of Off-Label Marketing 30

15 C. The Truth Begins To Emerge As Ra Medical Discloses Manufacturing
16 Problems, While Defendants Falsely Claim That The Problems Have
17 Been Fixed And Omit Other Material Information 31

18 1. Ra Medical Falsely Claims That “Production Limitations”
19 Stemming From Increased Demand Negatively Impacted Fourth
20 Quarter 2018 Sales..... 31

21 2. Ra Medical Falsely And/Or Misleadingly Assures Investors That
22 Problems With Catheter Production Have Been Resolved 33

23 D. The Truth Further Emerges As Defendants Admit That DABRA
24 Catheters Failed To Calibrate, Resulting In A Product Recall, And That
25 Ra Medical Engaged In Off-Label Marketing..... 35

26 1. Ra Medical Admits To The Product Issues And Its Audit
27 Committee Launches An Investigation Into An Anonymous
28 Complaint..... 35

2. Obscuring That It Had Been Engaged In A Covert Recall For
Months, Ra Medical Announces A Voluntary Recall..... 38

3. The Audit Committee Investigation Reports Its Findings..... 39

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- 4. Ra Medical Discloses A Criminal Investigation And Deficiencies In Its Internal Controls..... 41
- IX. RA MEDICAL ADMITS THAT THE REGISTRATION STATEMENT AND STATEMENTS MADE DURING THE CLASS PERIOD WERE MATERIALLY FALSE AND/OR MISLEADING AND/OR OMITTED MATERIAL FACTS 42
 - A. The Audit Committee Investigation Findings 42
 - B. Former Ra Medical Employees Corroborate The Audit Committee’s Findings..... 44
 - 1. Ra Medical Was Experiencing Calibration Issues With The DABRA Catheter At The Time Of The IPO 44
 - 2. Ra Medical Engaged In A Covert Product Recall..... 45
 - 3. Sales Representatives Were Directed To Market DABRA For Off-Label Uses..... 46
 - 4. Ra Medical Lacked An Adequate System to Document Expenses 48
 - 5. An Injury During The 2017 Pivotal Study Was Not Reported To The FDA 48
 - C. Recall Notice Suggests That Ra Medical Initiated The Recall Seven Months Before The IPO 49
 - D. Ra Medical Failed To Timely File Three MDRs..... 49
 - E. Ra Medical Settles DOJ Investigation Into Off-Label Marketing and Kickbacks to Physicians..... 50
- X. DEFENDANTS’ FALSE AND/OR MISLEADING STATEMENTS AND/OR OMISSIONS 51
 - A. False And/Or Misleading Statements And/Or Omissions Made In Connection With The IPO..... 51
 - 1. The Registration Statement And Roadshow Materials Touted Ra Medical’s Manufacturing Facility 51

1 2. The Registration Statement Warned Of A Hypothetical Product
2 Recall But Omitted Quality-Related Issues It Was Already
3 Experiencing 54
4 3. The Registration Statement And Roadshow Materials Omitted
5 To Disclose That Ra Medical Engaged In Off-Label Marketing
6 To Increase DABRA Sales 54
7 4. The Registration Statement And Roadshow Materials Omitted
8 To Disclose That Ra Medical Engaged In Potential Bribery To
9 Increase DABRA Sales..... 56
10 5. The Registration Statement And Roadshow Materials Omitted A
11 Patient’s Injury Experienced During The 2017 Pivotal Study For
12 DABRA 59
13 B. False And/Or Misleading Statements And/Or Omissions In Ra
14 Medical’s Code of Ethics and Conduct 60
15 C. False And/Or Misleading Statements And/Or Omissions Made In
16 Connection With The Announcement Of Ra Medical’s Third Quarter
17 2018 Financial Results 62
18 D. False And/Or Misleading Statements And/Or Omissions Made At
19 Biotech Showcase On January 8, 2019..... 70
20 E. False And/Or Misleading Statements And/Or Omissions Made In
21 Connection With The Announcement Of Ra Medical’s Fourth Quarter
22 2018 Financial Results 71
23 F. False And/Or Misleading Statements And/Or Omissions Made In
24 Connection With The Announcement Of Ra Medical’s First Quarter
25 2019 Financial Results 81
26 G. False And/Or Misleading Statements And/Or Omissions Regarding
27 The Product Recall..... 88
28 XI. LOSS CAUSATION 89
29 XII. POST-CLASS PERIOD EVENTS..... 93
30 XIII. ADDITIONAL SCIENTER ALLEGATIONS 94
31 XIV. UNDISCLOSED ADVERSE FACTS 97

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.